Latest PolyPid News & Updates

See the latest news and media coverage for PolyPid. We track all announcements, press releases, and industry mentions in real time, all in one place.

PolyPid

Developer of long-acting controlled-release medicines

polypid.com

Headquarters: Petah Tikva, Israel
Company type: Public company
Number of employees: 10–90
Industry: Pharmaceuticals

Last updated Today

Latest news about PolyPid

In short: PolyPid received FDA Priority Review for its D-PLEX100 NDA and secured a $320 million commercialization deal with Azurity Pharmaceuticals.

Company announcements

August 12 PolyPid

PolyPid reports Q2 2026 financial results and corporate update

FDA accepted D-PLEX100 NDA with Priority Review; Azurity partnership brings $30M upfront, with PDUFA date November 28, 2026.

July 29 PolyPid

PolyPid announces FDA acceptance of NDA with Priority Review for D-PLEX100

The FDA set a PDUFA date of November 28, 2026, nearly a quarter ahead of guidance, and triggered a $15 million milestone payment.

July 21 PolyPid

PolyPid announces exclusive partnership with Azurity Pharmaceuticals

PolyPid will receive over $320 million in milestone payments and tiered royalties for D-PLEX100 commercialization in US and Canada.

June 1 PolyPid

PolyPid completes NDA submission to FDA for D-PLEX100

The submission aims to prevent surgical site infections; PDUFA target in Q1 2027.

Media coverage

August 13 The Globe and Mail

PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

August 12 RTTNews

PolyPid Advances D-PLEX100; FDA Grants Priority Review

PolyPid (PYPD) received FDA Priority Review for D-PLEX100, with a PDUFA goal date of November 28, 2026. The company also secured a U.S. and Canada...

August 12 ScanX

PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA

PolyPid Ltd (NASDAQ: PYPD) reported Q2 2026 EPS of $(0.35), beating estimates by 7.89% as net losses narrowed 55% YoY to $7.8 million. Key drivers...

August 12 TradingView

PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 — TradingView News

FDA accepted NDA for D-PLEX 100 with Priority Review, setting a PDUFA goal date ahead of schedule. Secured $30 million in milestone payments through a...

Never miss news about PolyPid

Track PolyPid and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

PolyPid competitors & trending companies

Browse news for competitors to PolyPid and other trending companies.